This slideshow reviews drug information for BAVENCIO (avelumab), indicated for merkel cell carcinoma. Table of Contents Slide 3: Indication, Dosage, and AdministrationSlide 10: Use in Specific PopulationsSlide 13: Clinical PharmacologySlide 17: Warnings and PrecautionsSlide 22: Clinical Safety and EfficacySlide 30: Drug Storage and SupplySlide 33: References
This slideshow reviews drug information for IMLYGIC (talimogene laherparepvec), indicated for melanoma. Table of Contents Slide 3: Indication, Dosage, and AdministrationSlide 10: Use in Specific PopulationsSlide 13: Clinical PharmacologySlide 17: Warnings and PrecautionsSlide 21: Clinical Safety and EfficacySlide 27: Drug Storage and SupplySlide 30: References
This slideshow reviews drug information for ONIVYDE (liposomal irinotecan), indicated for pancreatic cancer. Table of Contents Slide 3: Indication, Dosage, and AdministrationSlide 8: Use in Specific PopulationsSlide 11: Clinical PharmacologySlide 16: Warnings and PrecautionsSlide 20: Clinical Safety and EfficacySlide 27: Drug Storage and SupplySlide 30: References
This slideshow reviews drug information for ERIVEDGE (vismodegib), indicated for basal cell carcinoma. Table of Contents Slide 3: Indication, Dosage, and AdministrationSlide 7: Use in Specific PopulationsSlide 10: Clinical PharmacologySlide 14: Warnings and PrecautionsSlide 19: Clinical Safety and EfficacySlide 25: Drug Storage and SupplySlide 28: References
This slideshow reviews drug information for CAPRELSA (vandetanib), indicated for medullary thyroid cancer. Table of Contents Slide 3: Indication, Dosage, and AdministrationSlide 9: Use in Specific PopulationsSlide 12: Clinical PharmacologySlide 17: Warnings and PrecautionsSlide 23: Clinical Safety and EfficacySlide 29: Drug Storage and SupplySlide 32: References
This slideshow reviews drug information for OPDIVO (nivolumab), indicated for urothelial carcinoma. Table of Contents Slide 3: Indication, Dosage, and AdministrationSlide 12: Use in Specific PopulationsSlide 15: Clinical PharmacologySlide 20: Warnings and PrecautionsSlide 32: Clinical Safety and EfficacySlide 41: Drug Storage and SupplySlide 44: References
This slideshow reviews drug information for ZELBORAF (vemurafenib), indicated for melanoma. Table of Contents Slide 3: Indication, Dosage, and AdministrationSlide 8: Use in Specific PopulationsSlide 11: Clinical PharmacologySlide 17: Warnings and PrecautionsSlide 23: Clinical Safety and EfficacySlide 32: Drug Storage and SupplySlide 35: References
This slideshow reviews drug information for RUBRACA (rucaparib), indicated for ovarian cancer. Table of Contents Slide 3: Indication, Dosage, and AdministrationSlide 7: Use in Specific PopulationsSlide 11: Clinical PharmacologySlide 15: Warnings and PrecautionsSlide 19: Clinical Safety and EfficacySlide 25: Drug Storage and SupplySlide 28: References
This slideshow reviews drug information for LARTRUVO (olaratumab), indicated for soft tissue sarcoma. Table of Contents Slide 3: Indication, Dosage, and AdministrationSlide 8: Use in Specific PopulationsSlide 11: Clinical PharmacologySlide 15: Warnings and PrecautionsSlide 19: Clinical Safety and EfficacySlide 26: Drug Storage and SupplySlide 29: References
This slideshow reviews drug information for TECENTRIQ (atezolizumab), indicated for metastatic non-small cell lung cancer. Table of Contents Slide 3: Indication, Dosage, and AdministrationSlide 10: Use in Specific PopulationsSlide 13: Clinical PharmacologySlide 17: Warnings and PrecautionsSlide 23: Clinical Safety and EfficacySlide 31: Drug Storage and SupplySlide 33: References
